ROME, April 18, 2016 /PRNewswire/ --
Angelini is an international group leader in the Rx and OTC pharmaceutical sector focused on Pain & Inflammation Disorders, Infection Control & Infectious Diseases, and Nervous System Diseases & Disorders.
(Logo: http://photos.prnewswire.com/prnh/20160418/356303LOGO )
Recently in the Infection Control & Infectious Diseases therapy area, Angelini entered into a license agreement with Allergan to commercialize dalbavancin, a second generation, semi-synthetic lipoglycopeptide, in several countries, which include Italy, Spain, Poland, Portugal and many Eastern European countries, including Russia and Turkey.
Dalbavancin is approved for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI).
Starting with the experience of the development of prulifloxacin, Angelini R&D gradually became more involved in Infection Control & Infectious Diseases, an area where pharmacological research has become a priority focusing on emerging antibiotic resistance. Angelini has an outstanding R&D pipeline in anti-infectives, including research on New Chemical Entities and the lifecycle management of the existing products.
Data from Angelini research projects elucidate the mechanism of action of original compounds that act as dual topoisomerase II or as -lactamase inhibitors, and further characterize their enzymatic and microbiological properties. They also allowed researchers at Angelini to identify novel inhibitors.
Moreover, clinical studies with prulifloxacin permitted to establish the correct dose regimen for renal impaired patients.
These data from Angelini were presented at the 26th European Congress in Clinical Microbiology and infectious Diseases (ECCMID), 09 - 12 April 2016 / Nertherlands, Amsterdam:
Poster Session: "Discovery of more new antibacterial drugs"
- Novel class of dual topoisomerase II inhibitors: study on mode of action
- Identification of novel IMP-1, VIM-1 and NDM-1 metallo-beta-lactamase inhibitors
- Advanced use of high-throughput screening tools for the identification of novel OXA-48
beta-lactamase inhibitors for infection treatment
ePosters Session: "Pharmacokinetics/Pharmacodynamics of antibacterial drugs and therapeutic drug monitoring"
- An in depth investigation on prulifloxacin dosage adjustment in mild, moderate and
severe renal impairment
Angelini was the only Italian Pharmaceutical company to be present at the ECCMID congress where they presented their innovative pipeline data and had a major presence in the exhibition hall.
Dalbavancin for injection is a second generation, semi-synthetic lipoglycopeptide, which consists of a lipophilic side-chain added to an enhanced glycopeptide backbone. Dalbavancin is the first and only IV antibiotic approved for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI), with both a two-dose regimen of 1000 mg followed one week later by 500 mg, each administered over 30 minutes, and a single dose regimen of 1500 mg also administered over 30 minutes. Dalbavancin demonstrates bactericidal activity in vitro against a range of Gram-positive bacteria, such as Staphylococcus aureus (including methicillin-resistant, also known as MRSA, strains) and Staphylococcus pyogenes, as well as certain other streptococcal species.
Angelini has licensed dalbavancin from Durata Therapeutics, now Allergan plc, to commercialize the product in several territories, including Italy, Spain, Poland, Portugal, many Eastern European countries, Russia and Turkey.
Angelini, a private international group, is a leader in the health and wellness area of the pharmaceutical and basic commodities sectors. Founded in Italy in the early 20th century, it now has branches in 20 countries and employs about 5.000 people. The pharmaceutical sector is the core business of the group, representing over 50% of the Angelini group, EUR1.5 billion 2015 revenue.
Angelini pharmaceutical products are available in over 60 countries through its branches and an extensive network of licensees and strategic agreements with local pharmaceutical companies.
The company portfolio focuses mainly on pain relief, inflammation, CNS, anti-infectives, gynecology and has a strong position in the OTC market. The R&D department is currently working on several projects in the area of Pain & Inflammation Disorders, Nervous System Diseases & Disorders, and Infection Control & Infectious Diseases. In the latter, R&D is active with discovery programs, including private-public projects with New Chemical Entities, as well as clinical studies with already marketed products fully developed in Europe by Angelini.
CONTACT: For further information: Angelini Group, +39 06 910451 , SerenaTongiani, Chief Scientific Officer, S.Tongiani@angelini.it, FrancescaRomana Imbrighi, Strategic Portfolio Marketing Director,F.Imbrighi@angelini.it, Media Contacts: Value Relations, +39 02 2042491,Francesca Alibrandi, email@example.com, Cristina Depaoli,firstname.lastname@example.org